Last reviewed · How we verify
Neo-Calglucon (CALCIUM GLUBIONATE)
Neo-Calglucon (generic name: CALCIUM GLUBIONATE) is a calcium glubionate drug. It is currently in Phase 2 development for Hypocalcemia.
Neo-Calglucon works by replenishing calcium stores in the body.
Neo-Calglucon is a small molecule calcium compound used in dental procedures, specifically in pulpotomy treatments for primary teeth. It has been studied in clinical trials for various conditions, including dentin caries and esophageal adenocarcinoma, but its primary use is in dental applications.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CALCIUM GLUBIONATE |
|---|---|
| Drug class | calcium glubionate |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Think of calcium like a key that unlocks the doors to your cells, allowing them to function properly. When you have low calcium levels, your cells can't work as well as they should, leading to problems like muscle cramps and weakness. Taking Neo-Calglucon helps to restore the right balance of calcium in your body, so your cells can function normally again.
Approved indications
- Hypocalcemia
Common side effects
- Liver injury
- Psoriatic arthropathy
- Glossodynia
- Pemphigus
- Systemic lupus erythematosus
- Hand deformity
- Wound
- Duodenal ulcer perforation
- Rheumatoid arthritis
- Fibromyalgia
- Contraindicated product administered
- Rheumatic fever
Key clinical trials
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (PHASE1)
- Effect of 1% Melatonin Gel Versus Calcium Hydroxide as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp. (NA)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
- Clinical Evaluation of an Experimental Remineralization Product (NA)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neo-Calglucon CI brief — competitive landscape report
- Neo-Calglucon updates RSS · CI watch RSS
Frequently asked questions about Neo-Calglucon
What is Neo-Calglucon?
How does Neo-Calglucon work?
What is Neo-Calglucon used for?
What is the generic name of Neo-Calglucon?
What drug class is Neo-Calglucon in?
What development phase is Neo-Calglucon in?
What are the side effects of Neo-Calglucon?
Related
- Drug class: All calcium glubionate drugs
- Therapeutic area: All drugs in Other
- Indication: Drugs for Hypocalcemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing